Products for Research Use Only

Drospirenone-d4

CAT: 0804-HY-B0111SSize: 2.5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-B0111SSize:2.5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Drospirenone-d4 is the deuterium labeled Drospirenone. Drospirenone (Dihydrospirorenone) is a synthetic progestin that is an analog to spironolactone[1][2].
CAS Number
2376035-94-6
Product Name Alternative
Dihydrospirorenone-d4
UNSPSC
12352005
Hazard Statement
H360
Target
Isotope-Labeled Compounds; Progesterone Receptor
Type
Isotope-Labeled Compounds
Related Pathways
Others; Vitamin D Related/Nuclear Receptor
Applications
Metabolism-protein/nucleotide metabolism
Field of Research
Endocrinology
Purity
0.9852
Solubility
10 mM in DMSO
Smiles
C[C@@]12[C@](OC3=O)(C([2H])([2H])C3([2H])[2H])[C@@H](C4)[C@@H]4[C@@]1([H])[C@@]([C@@H]5[C@H]6C5)([H])[C@]([C@](C6=CC7=O)(CC7)C)([H])CC2
Molecular Formula
C24H26D4O3
Molecular Weight
370.52
Precautions
H360
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Fuhrmann, U., et al., The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential. Contraception, 1996. 54 (4) : p. 243-51.|[3]Muhn, P., et al., Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. Pharmacological characterization in animal models. Contraception, 1995. 51 (2) : p. 99-110.|[4]Warming, L., et al., Safety and efficacy of drospirenone used in a continuous combination with 17beta-estradiol for prevention of postmenopausal osteoporosis. Climacteric, 2004. 7 (1) : p. 103-11.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported